As filed with the Securities and Exchange Commission on March 13, 2018

Registration No. 333-      

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 


 

Corvus Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

46-4670809

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

863 Mitten Road, Suite 102

Burlingame, CA 94010

(650) 900-4520

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 


 

2016 Equity Incentive Award Plan

(Full Title of the Plan)

 


 

Richard A. Miller, M.D.

President and Chief Executive Officer

Corvus Pharmaceuticals, Inc.

863 Mitten Road, Suite 102

Burlingame, CA 94010

(650) 900-4520

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 


 

Copies to:

Alan C. Mendelson, Esq.  

Kathleen M. Wells, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

Facsimile: (650) 463-2600

 


 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

o

 

 

Accelerated filer

x

Non-accelerated filer

o

(Do not check if a smaller reporting company)

 

Smaller reporting company

o

Emerging growth company

x

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Each Class of
Securities to be Registered

 

Amount
to be
Registered
(1)

 

Proposed
Maximum
Offering Price
Per Share
(2)

 

Proposed
Maximum
Aggregate Offering
Price Per Share

 

Amount of
Registration Fee

 

Common Stock, $0.0001 par value per share

 

840,000

(3)

$

9.96

 

$

8,366,400.00

 

$

1,041.62

 

(1)                                 Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the 2016 Equity Incentive Award Plan (the “2016 Plan”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.

(2)                                 This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant’s common stock as reported on The NASDAQ Global Select Market on March 12, 2017, which is $9.96.

(3)                                 Represents the additional shares of common stock available for future issuance under the 2016 Plan resulting from an annual increase as of January 1, 2018.

 

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

 

 

 



 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 840,000 shares of the Registrant’s common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456 and 333-216590) are effective, as a result of the operation of an automatic annual increase provision therein.

 

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

FORM S-8

 

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016 and March 10, 2017 (File Nos. 333-210456 and 333-216590) are incorporated by reference herein.

 

2



 

Exhibit Index

 

 

 

 

 

 

 

Filed

Exhibit

 

 

 

Incorporated by Reference

 

Herewith

Number

 

Exhibit Description

 

Form

 

Date

 

Number

 

 

 

 

 

 

 

 

 

 

 

 

 

  4.1

 

Amended and Restated Certificate of Incorporation.

 

8-K

 

3/29/2016

 

3.1

 

 

  4.2

 

Amended and Restated Bylaws.

 

8-K

 

3/29/2016

 

3.2

 

 

  4.3

 

Form of Common Stock Certificate.

 

S-1

 

1/4/2016

 

4.2

 

 

  4.4

 

Amended and Restated Investors’ Rights Agreement, dated September 16, 2015, by and among Corvus Pharmaceuticals, Inc. and the investors listed therein.

 

S-1/A

 

2/8/2016

 

4.3

 

 

  5.1

 

Opinion of Latham & Watkins LLP.

 

 

 

 

 

 

 

X

23.1

 

Consent of independent registered public accounting firm.

 

 

 

 

 

 

 

X

23.2

 

Consent of Latham & Watkins LLP (included in Exhibit 5.1).

 

 

 

 

 

 

 

X

24.1

 

Power of Attorney. Reference is made to the signature page to the Registration Statement.

 

 

 

 

 

 

 

X

99.2(a)#

 

2016 Equity Incentive Award Plan.

 

S-8

 

3/29/2016

 

99.2(a)

 

 

99.2(b)#

 

Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.

 

S-1

 

1/4/2016

 

10.5(b)

 

 

99.2(c)#

 

Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Agreement under the 2016 Equity Incentive Award Plan.

 

S-1

 

1/4/2016

 

10.5(c)

 

 

99.2(d)#

 

Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.

 

S-1

 

1/4/2016

 

10.5(d)

 

 

 


 

 

#Indicates management contract or compensatory plan.

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Burlingame, California, on this 13th day of March, 2018.

 

 

Corvus Pharmaceuticals, Inc.

 

 

 

 

By:

/s/ Richard A. Miller

 

 

Richard A. Miller, M.D.

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

/s/ Richard A. Miller

 

President, Chief Executive Officer and Director

 

March 13, 2017

 

Richard A. Miller M.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 

/s/ Leiv Lea

 

Chief Financial Officer

 

March 13, 2017

 

Leiv Lea

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

 

/s/ Ian T. Clark

 

Director

 

March 13, 2017

 

Ian T. Clark

 

 

 

 

 

 

 

 

 

 

 

/s/ Elisha P. (Terry) Gould

 

Director

 

March 13, 2017

 

Elisha P. (Terry) Gould

 

 

 

 

 

 

 

 

 

 

 

/s/ Steve E. Krognes

 

Director

 

March 13, 2017

 

Steve E. Krognes

 

 

 

 

 

 

 

 

 

 

 

/s/ Peter Moldt, Ph.D.

 

Director

 

March 13, 2017

 

Peter Moldt, Ph.D.

 

 

 

 

 

 

 

 

 

 

 

/s/ Scott W. Morrison

 

Director

 

March 13, 2017

 

Scott W. Morrison

 

 

 

 

 

 

 

 

 

 

 

/s/ Peter Thompson, M.D.

 

Director

 

March 13, 2017

 

Peter Thompson, M.D.

 

 

 

 

 

 

4


Exhibit 5.1

 

 

140 Scott Drive

 

Menlo Park, California 94025

 

Tel: +1.650.328.4600 Fax: +1.650.463.2600

 

www.lw.com

 

 

FIRM / AFFILIATE OFFICES

Beijing

Moscow

Boston

Munich

Brussels

New York

 

Century City

Orange County

 

Chicago

Paris

 

Dubai

Riyadh

March 13, 2018

Düsseldorf

Rome

 

Frankfurt

San Diego

 

Hamburg

San Francisco

 

Hong Kong

Seoul

 

Houston

Shanghai

 

London

Silicon Valley

 

Los Angeles

Singapore

 

Madrid

Tokyo

 

Milan

Washington, D.C.

 

Corvus Pharmaceuticals, Inc.

863 Mitten Road, Suite 102
Burlingame, CA 94010

 

Re:                             Registration Statement on Form S-8; 840,000 shares of Common Stock of Corvus Pharmaceuticals, Inc., par value $0.0001 per share

 

Ladies and Gentlemen:

 

We have acted as special counsel to Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 840,000 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) (the “Shares”) issuable under the 2016 Equity Incentive Award Plan (the “Plan”).

 

The Shares are included in a registration statement on Form S—8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 13, 2018 (the “Registration Statement”).  This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.

 

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.  With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.  We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

 



 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Plan, assuming in each case that the individual issuances, grants or awards under the Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act.  We consent to your filing this opinion as an exhibit to the Registration Statement.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

 

Very truly yours,

 

 

 

/s/ Latham & Watkins LLP

 

2


Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 1, 2018 relating to the financial statements, which appears in Corvus Pharmaceuticals, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

/s/ PricewaterhouseCoopers LLP

 

San Jose, CA

March 13, 2018